Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies ... with the three-drug combination compared ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies ... with the three-drug combination compared ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies ... with the three-drug combination compared ...

Opens in a new tab or window SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that converted ...

BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving systemic therapy in a real-world setting, as shown in findings from a ...